​

 

McGivney Global Advisors is a leader in product strategy for specialty pharmaceutical and biotech products, with a particular focus on oncology and cancer care and expertise ranging across specialty markets including osteoporosis, hepatitis C, ophthalmology, rheumatology/immunology, virology, orphan diseases, and supportive care. 

 

Our experts have not only advised the leading biopharma companies on their pre-launch and launch market access and payer strategies, but have also built key components of the U.S. coverage system and payer policies through previous leadership roles at NCCN, Aetna, biotech and pharma companies and strategic consulting firm.

 

McGA is uniquely established to help you position your specialty therapeutics and diagnostics for a successful launch and lifecycle through positioning in guidelines and compendia, strategies and submissions (e.g., NCCN and other CMS-recognized compendia and pathways), value messaging to public and private payers and stakeholders, and navigation of coverage policy and utilization management processes. Our team's collective NCCN, Aetna, industry and consulting experience distinguishes McGA as the leader in product positioning strategy.